Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Roland Suck"'
Autor:
Florentina Rus, Christine Warmbold, Roland Suck, Arnd Petersen, Artur J. Ulmer, Thomas Roeder, Karin Uliczka, Neal S. Silverman, Holger Heine
Publikováno v:
The Journal of Immunology. 190:366-371
Some allergens with relevant protease activity have the potential to directly interact with host structures. It remains to be elucidated whether this activity is relevant for developing their allergenic properties. The major goal of this study was to
Publikováno v:
Clinical & Experimental Allergy. 39:1358-1369
Summary Background Group 1 allergens from grass pollen (e.g. Phl p 1, the major allergen of timothy grass Phleum pratense) cause IgE reactivity in about 95% of allergic subjects and exist in all grass species. The respiratory epithelium represents a
Autor:
Friedrich Horak, Gabrielle Pauli, Ashok Purohit, M. Kronqvist, B. Weber, Roland Suck, H. Fiebig, Oliver Cromwell, M. van Hage, R. Grönneberg, Rudolf Valenta, Verena Niederberger
Publikováno v:
Clinical & Experimental Allergy. 38:1514-1525
Summary Background Birch pollen and pollen from related trees of the Fagales order are a major cause of allergic rhinitis, conjunctivitis, and asthma through the spring season in northern and central Europe. Objective To investigate the clinical effe
Autor:
Brigitte Schäffer, Oliver Cromwell, Roland Suck, Timo Kamionka, D V Siva Charan, Andreas Nandy, Helmut Fiebig, Bernhard H. F. Weber, Walter Keller, Rüdiger Wahl, Ruth Birner-Grünberger, Arnd Petersen
Publikováno v:
Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics. 1764:1701-1709
Recombinant production in bacteria of soluble and monomeric Phl p 1, a major allergen of Timothy grass pollen, has proved to be very problematic. In order to facilitate expression and purification of this allergen, a recombinant variant was designed
Autor:
Roland Suck, Oliver Cromwell
Publikováno v:
Current Pharmaceutical Analysis. 2:249-257
Autor:
Andreas Nandy, Jens Kettner, Roland Suck, Helmut Fiebig, Oliver Cromwell, Helga Kahlert, Annemie Narkus
Publikováno v:
Immunology and Allergy Clinics of North America. 26:261-281
Recombinant DNA technology has delivered the prospect of a new generation of preparations for allergen-specific immunotherapy. The first clinical studies with recombinant allergens have yielded encouraging results, suggesting that there is a good cha
Publikováno v:
Journal of Allergy and Clinical Immunology. 116:608-613
Background Allergen-specific immunotherapy uses aqueous extracts of natural source materials as a basis for preparations to downregulate the allergic response. Recombinant DNA technology has enabled the cloning of many allergens, thus facilitating in
Autor:
Oliver Cromwell, Andreas Nandy, Helga Kahlert, Roland Suck, Bernhard H. F. Weber, Helmut Fiebig
Publikováno v:
Methods. 32:300-312
The cloning and production of an increasing number of allergens through the use of DNA technology has provided the opportunity to use these proteins instead of natural allergen extracts for the diagnosis and therapy of IgE-mediated allergic disease.
Autor:
Thomas L. Diepgen, Helmut Fiebig, Oliver Kuss, Josef Thalhamer, Vera Mahler, Oliver Cromwell, Rudolf Valenta, Susanne Vrtala, Arnulf Josef Hartl, Gerold Schuler, Dietrich Kraft, Roland Suck
Publikováno v:
Clinical Experimental Allergy. 34:115-122
Summary Background We have recently engineered recombinant derivatives of the major birch pollen allergen Bet v 1 (rBet v 1 fragments and trimer) with strongly reduced allergenic activity. Objective The aim of this study was the in vivo characterizat
Autor:
Arnd Petersen, Susan J. Hagen, Oliver Cromwell, Helmut Fiebig, Roland Suck, Wolf-Meinhard Becker
Publikováno v:
Journal of Allergy and Clinical Immunology. 107:856-862
Background: Determination of the allergen composition of an extract is essential for the improvement of hyposensitization therapy. Surprisingly, although grass pollen extracts have been studied intensively for 20 years, a further major allergen, Phl